Roche prices cancer drug at $17K a month

(By Alia Paavola for Becker’s Hospital Review)

Roche has priced its cancer treatment Rozlytrek at $17,050 per month, about half the cost of a similar drug sold by Eli Lilly and Bayer, according to STAT.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.

 

Leave a Reply